Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients
Open Access
- 4 October 2022
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (2) , 175-182
Abstract
This was a multicenter clinical trial of rituximab, a chimeric monoclonal IgG antibody directed against CD20, for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. In total, 20 patients were treated with two doses of rituximab (1000 mg; 2 weeks apart) on days 0 and 14. The primary end point was the proportion of patients who achieved complete or partial remission on day 168 following the first rituximab dose. Of the 20 enrolled patients, 11 (55%) and four (20%) achieved complete and partial remission, respectively; therefore, remission was achieved in a total of 15 patients (75.0% [95% confidence interval, 50.9%–91.3%]). It was demonstrated that the remission rate was greater than the prespecified threshold (5%). In addition, a significant improvement in clinical score (Pemphigus Disease Area Index) and decrease in serum anti‐desmoglein antibody level were observed over time. Four serious adverse events (heart failure, pneumonia, radial fracture, and osteonecrosis) were recorded in two patients, of which only pneumonia was considered causally related with rituximab. The level of peripheral blood CD19‐positive B lymphocytes was decreased on day 28 after rituximab treatment and remained low throughout the study period until day 168. Our results confirm the efficacy and safety of rituximab therapy for refractory pemphigus in Japanese patients.Keywords
Funding Information
- Japan Agency for Medical Research and Development (19ek0109251h003)
This publication has 27 references indexed in Scilit:
- Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-upJournal of the American Academy of Dermatology, 2012
- Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patientsJournal of the American Academy of Dermatology, 2011
- Reliability and Convergent Validity of Two Outcome Instruments for PemphigusJournal of Investigative Dermatology, 2009
- Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpuraInternational Journal of Hematology, 2009
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusNew England Journal of Medicine, 2007
- Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinionBritish Journal of Dermatology, 2007
- Pemphigus, Bullous Impetigo, and the Staphylococcal Scalded-Skin SyndromeNew England Journal of Medicine, 2006
- The therapeutic potential of anti-CD20Clinical Immunology, 2005
- Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumaticaArthritis & Rheumatism, 1997